Unraveling angioedema: diagnostic challenges and emerging therapies.

Front Immunol · 2025 · PMC12521201 · PMID 41103407

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

borderline significanceno p-value reported

Dupilumab demonstrated a −8.5-point reduction in Urticaria Activity Score over 7 days (UAS7) and a −4.2-point reduction in Itch Severity Score (ISS7) versus placebo in omalizumab-naïve patients; in omalizumab-intolerant or incomplete responders, only modest benefits were observed (UAS7 −5.8 points, borderline significance; ISS7 not significant) ( 4 ).

also in 7,017 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.